{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:53:48Z","timestamp":1790834028636,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Gonadotropin-releasing hormone (GnRH) analogs are the standard treatment for central precocious puberty (CPP). Although there are numerous varieties of GnRH agonists, the effectiveness of 1-monthly compared with 3-monthly Leuprolide acetate is still restricted. The objective of this study was to evaluate the outcomes of CPP treatment with Leuprolide acetate at a 1-monthly dosage of 3.75 mg, in comparison to a dosage of 11.25 mg administered every 3 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This retrospective cohort study involved 143 girls diagnosed with CPP with 72 of them receiving the monthly treatment regimen and 71 receiving the 3-monthly treatment regimen. Anthropometric measurements were compared at the start and end of the therapy. The rates and level of LH suppression were assessed six months after therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The regimen administered every 3 months showed more significant suppression of LH. The 3-monthly group showed lower actual height and degree of bone age advancement at the end of therapy. However, the predicted adult height (PAH) remained comparable in both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The 3-monthly treatment showed greater hormonal and growth suppression effects, but there was no significant difference in PAH between the two groups.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1390674","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T13:03:26Z","timestamp":1714136606000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment"],"prefix":"10.3389","volume":"15","author":[{"given":"Thanaporn","family":"Thaneetrakool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suphab","family":"Aroonparkmongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattakarn","family":"Numsriskulrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vichit","family":"Supornsilchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suttipong","family":"Wacharasindhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khomsak","family":"Srilanchakon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00380-0","article-title":"Causes, diagnosis, and treatment of central precocious puberty","volume":"4","author":"Latronico","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0800459","article-title":"Precocious puberty","volume":"358","author":"Carel JC","year":"2008","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1783","article-title":"Consensus statement on the use of gonadotropin-releasing hormone analogs in children","volume":"123","author":"Carel","year":"2009","journal-title":"Pediatrics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad081","article-title":"Approach to the patient: central precocious puberty","volume":"108","author":"Kilberg","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00036","article-title":"Treatment of central precocious puberty","volume":"3","author":"Eugster","year":"2019","journal-title":"J Endocr Soc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101262","DOI":"10.1016\/j.beem.2019.01.003","article-title":"Central precocious puberty, functional and tumor-related","volume":"33","author":"Soriano-Guillen","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14410","article-title":"Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: A systematic review and meta-analysis","volume":"94","author":"Luo","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.12.6203","article-title":"Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function","volume":"84","author":"Sabine","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.6.5647","article-title":"Final height after long-term treatment with triptorelin slow release for central precoious puberty: Importance of statural growth after interruption of treatment","volume":"84","author":"Carel","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2001-020243","article-title":"Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg)","volume":"87","author":"Carel","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02056","article-title":"Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty","volume":"154","author":"Carel","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4471","article-title":"36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty","volume":"99","author":"Lee","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1159\/000441497","article-title":"Central precocious puberty: adult height in girls treated with quarterly or monthly gonadotropin-releasing hormone analog triptorelin","volume":"84","author":"Bertelloni","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"B14","volume-title":"Radiographic atlas of skeletal development of the hand and wrist. 2nd ed","author":"Greulich","year":"1959"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1500","article-title":"Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty","volume":"91","author":"Badaru","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2704","article-title":"Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty","volume":"97","author":"Lee","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000442523","article-title":"Assessment of estradiol response after depot triptorelin administration in girls with central precocious puberty","volume":"85","author":"Freire","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000456545","article-title":"Meta-analysis of paediatric patients with central precocious puberty treated with intramuscular triptorelin 11.25 mg 3-month prolonged-release formulation","volume":"87","author":"Durand","year":"2017","journal-title":"Horm Res Paediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1043293","DOI":"10.1155\/2022\/1043293","article-title":"Efficacy of Leuprorelin 3-month depot (11.25 mg) compared to 1-month depot (3.75 mg) for central precocious puberty in Chinese girls: a prospective cohort study","volume":"2022","author":"Yang","year":"2022","journal-title":"Int J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000056540","article-title":"Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormonal levels and phamacokinetic profile in patients with advanced prostate cancer","volume":"60","author":"Tunn","year":"1998","journal-title":"Urologia Internationalis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-200241070-00003","article-title":"Clinical pharmacokinetics of depot leuprorelin","volume":"41","author":"Periti","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2040134.067","article-title":"Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty","volume":"26","author":"Jeon","year":"2021","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e219","article-title":"Efficacy of triptorelin 3-month depot compared to 1-month depot for the treatment of korean girls with central precocious puberty in single tertiary center","volume":"36","author":"Chung","year":"2021","journal-title":"J Korean Med Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1390674\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T13:03:29Z","timestamp":1714136609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1390674\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":23,"alternative-id":["10.3389\/fendo.2024.1390674"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1390674","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"article-number":"1390674"}}